Skip to main content
Clinical Trials/CTRI/2022/09/046101
CTRI/2022/09/046101
Not yet recruiting
Phase 2

Comparative Clinical and Radiographic Evaluation of the Efficacy of Beta Tricalcium Phosphate (AliveossÃ?®) with Titanium Platelet Rich Fibrin (T-PRF ) and Beta Tricalcium Phosphate (AliveossÃ?® ) with Injectable Platelet Rich Fibrin (i-PRF) in the Treatment of Intrabony Defects in Chronic Periodontitis Patients ââ?¬â?? A Randomized Clinical Trial

Dr Sayali Gotpagar0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Sayali Gotpagar
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Sayali Gotpagar

Eligibility Criteria

Inclusion Criteria

  • 1\)Patients diagnosed with Chronic Periodontitis.
  • 2\)Patients who are non smokers or do not consume tobacco in any other form.
  • 3\)Patients are in good systemic health with no contraindication to periodontal surgery.
  • 4\)Patients having pocket depths \>5mm, intraosseous defects \> 3mm and with radiographic
  • evidence of vertical / angular bone loss in the affected sites.
  • 5\)Involved teeth to be vital and asymptomatic.

Exclusion Criteria

  • 1\) One\-walled osseous defects.
  • 2\) Patients suffering from any systemic diseases or with a compromised immune system.
  • 3\) Patients who had received any type of periodontal therapy for the past 6 months.
  • 4\) Patients taking immunosuppressant drugs like corticosteroids.
  • 5\) Patients with a known history of allergy to Doxycycline or Chlorhexidine or any other
  • medicine used in the study.
  • 6\) Patients showing unacceptable oral hygiene compliance during / after Phase I
  • periodontal therapy.
  • 7\) Patients taking any drug known to cause gingival enlargement.
  • 8\) Pregnant and/or lactating mothers.

Outcomes

Primary Outcomes

Not specified

Similar Trials